Henry Ford Health

Henry Ford Health Scholarly Commons
Cardiology Articles

Cardiology/Cardiovascular Research

4-8-2021

Complications and failure modes of covered coronary stents:
Insights from the MAUDE database
Michael Megaly
Magdi Zordok
Amgad Mentias
Yashasvi Chugh
Rupinder S Buttar

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/cardiology_articles

Recommended Citation
Megaly M, Zordok M, Mentias A, Chugh Y, Buttar RS, Basir MB, Burke MN, Karmpaliotis D, Azzalini L,
Alaswad K, and Brilakis ES. Complications and failure modes of covered coronary stents: Insights from
the MAUDE database. Cardiovasc Revasc Med 2021.

This Article is brought to you for free and open access by the Cardiology/Cardiovascular Research at Henry Ford
Health Scholarly Commons. It has been accepted for inclusion in Cardiology Articles by an authorized
administrator of Henry Ford Health Scholarly Commons.

Authors
Michael Megaly, Magdi Zordok, Amgad Mentias, Yashasvi Chugh, Rupinder S Buttar, Mir B. Basir, M.
Nicholas Burke, Dimitrios Karmpaliotis, Lorenzo Azzalini, Khaldoon Alaswad, and Emmanouil S. Brilakis

This article is available at Henry Ford Health Scholarly Commons: https://scholarlycommons.henryford.com/
cardiology_articles/836

CARREV-02316; No of Pages 4
Cardiovascular Revascularization Medicine xxx (xxxx) xxx

Contents lists available at ScienceDirect

Cardiovascular Revascularization Medicine

Complications and failure modes of covered coronary stents: Insights
from the MAUDE database
Michael Megaly a,1, Magdi Zordok b,1, Amgad Mentias c, Yashasvi Chugh d, Rupinder S. Buttar e, Mir B. Basir f,
M. Nicholas Burke d, Dimitrios Karmpaliotis g, Lorenzo Azzalini h, Khaldoon Alaswad f, Emmanouil S. Brilakis d,⁎
a

Division of Cardiology, Banner University Medical Center/University of Arizona, Phoenix, AZ, United States of America
Department of Medicine, Steward Carney Hospital, Boston, MA, United States of America
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, United States of America
d
Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, United States of America
e
Department of Medicine, Rochester Regional Health, Rochester, NY, United States of America
f
Department of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI, United States of America
g
Department of Cardiovascular Medicine, Columbia University, New York, NY, United States of America
h
Division of Cardiology, VCU Health Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, United States of America
b
c

a r t i c l e

i n f o

Article history:
Received 27 February 2021
Received in revised form 21 March 2021
Accepted 5 April 2021
Available online xxxx
Keywords:
Covered stents
Graftmaster
PK papyrus

a b s t r a c t
Background: Data on the mechanisms of failure of covered coronary stents [Graftmaster, PK Papyrus] are limited.
Methods: We queried the “Manufacturer and User Facility Device Experience” (MAUDE) database between August 2018 (when the PK Papyrus stent was FDA approved) and December 2020 for reports on covered coronary
stents.
Results: We identiﬁed 299 reports in the MAUDE database (after excluding duplicates, peripheral vascular reports, and incomplete records) (Graftmaster n = 225, PK Papyrus n = 74). The most common mechanism of failure of covered stents was failure to deliver the stent (46.2%), followed by stent dislodgement (22.4%) and failure
to seal the perforation (19.7%). Failure to deliver the stent was more often reported with Graftmaster compared
with PK Papyrus (59.1% vs. 6.8%, p < 0.001). Stent dislodgement was more often reported with PK Papyrus compared with Graftmaster (75.7% vs. 4.9%, p < 0.001) and was managed by device retrieval or by crushing the stent.
Conclusions: The most common failure mechanisms of covered stents are failure of delivery, stent dislodgement,
and failure to seal the perforation. Failure of delivery was more common with Graftmaster, while stent dislodgement was more common with PK Papyrus. Further improvements in covered stent design are needed to optimize
deliverability and minimize the risk of complications.
© 2021 Elsevier Inc. All rights reserved.

1. Introduction
Coronary artery perforation (CAP) is a rare but potentially lifethreatening complication of percutaneous coronary intervention (PCI)
[1], most commonly occurring as a large vessel perforation [2]. It occurs
in approximately 0.2–3% of all PCI procedures with a higher incidence in
more complex lesions, such as chronic total occlusions [3] and calciﬁed
lesions requiring the use of atherectomy [4,5,6]. The incidence of CAP
has not declined over time [7].

Abbreviation: MAUDE, Manufacturer and User Facility Device Experience database;
CAP, coronary artery perforation; PCI, percutaneous coronary intervention.
⁎ Corresponding author at: Minneapolis Heart Institute and Minneapolis Heart Institute
Foundation, Abbott Northwestern Hospital, 920 E 28th Street #300, Minneapolis, MN
55407, United States of America.
E-mail address: esbrilakis@gmail.com (E.S. Brilakis).
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Covered stents can successfully seal large vessel CAP and some distal
vessel perforation cases, [8] obviating the need for emergency cardiac
surgery [9]. In the United States, two covered stents have received humanitarian device exemption by the Food and Drug Administration
(FDA), the polytetraﬂuoroethylene (PTFE) covered Graftmaster stent
(Abbott Vascular, Santa Clara, CA) and the polyurethane PK Papyrus
stent (Biotronik, Lake Oswego, OR). We investigated the Manufacturer
and User Facility Device Experience (MAUDE) database for reports on
the failure of the aforementioned devices failure after approval of the
PK Papyrus stent (Fig. 1).
2. Materials and methods
The FDA's MAUDE database is an online database of adverse events
caused by an approved medical device. Reporting to the Maude registry
is either mandatory (for manufacturers and device user facilities) or voluntary (for healthcare professionals, patients, and consumers). We
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Fig. 1. Failure mechanisms of covered stents as reported to the MAUDE registry.

searched the database from August 2018 (date of approval of Papyrus
stent in the United States) to December 2020 for reports on the covered
coronary stents failure (Fig. 2).
The database was last accessed on January 7th, 2021, by two independent reviewers (MZ and MM). The MAUDE database is publicly
available and de-identiﬁed; therefore, no institutional review board approval was required for this study.

2.1. Outcomes and statistical analysis
The primary outcome of this study was the mechanisms of failure of
covered stents. Secondary outcomes included clinical consequences of
device failure. Categorical variables were described as numbers and percentages and were analyzed using Pearson's chi-square or Fisher's exact
tests. A value of p < 0.05 was considered signiﬁcant, and p-values are

Fig. 2. Failure mechanisms of covered stents according to each stent type as reported the MAUDE registry.
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reports (23.1%) for the Graftmaster and seven reports (9.5%) for the Papyrus PK) (Table 1).
Failure to achieve full expansion of the stent was found in 3% of reports, with no difference between stent types. Emergency surgery was
reported in 9.4%, and death in 19.1%. In-hospital mortality was found
to higher in the Graftmaster reports compared with the PK Papyrus reports (23.6% vs. 5.4%) (Table 1).

two-sided where possible. All statistical calculations were performed
with IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM
Corp (2017).
3. Results
A total of 422 reports were found during the study period. After excluding incomplete reports (n = 12), duplicate reports (n = 45), and reports in peripheral interventions (n = 92), our ﬁnal cohort included 299
reports related to coronary covered stents failure. Of those, 225 reports
were for the Graftmaster and 74 for the Papyrus stent (Table 1). Stent
lengths and diameters were reported in most of the events. The most
common diameter of the failed stents was 2.8 mm for the Graftmaster
(50.7% of the reports) and 2.5 mm for the Papyrus (41.9% of the reports)
(Table S1). The most common stent lengths were 19 mm (49.3%) and
15 mm (48.6%), for the Graftmaster and the Papyrus PK, respectively
(Table S2).

4. Discussion
Our study is the ﬁrst to report the mechanisms of failure of covered
stents after the PK Papyrus approval in the United States. Our ﬁndings
can be summarized as follows: 1) the most common mechanism of covered stents failure was the inability to deliver the stent, followed by
stent dislodgment, and failure to seal the perforation; 2) failure to deliver the stent was more reported with the Graftmaster stent; 3) stent
dislodgement was more reported with the PK Papyrus stent and was
managed by device retrieval or crushing the stent; and 4) In-hospital
mortality was found to higher in the Graftmaster reports compared
with the PK Papyrus reports.
Coronary perforations can be classiﬁed according to severity using
the Ellis classiﬁcation, with Type III perforations being ≥1 mm diameter
with contrast streaming and cavity spilling [10]. Covered stents can help
seal types II and III perforations in large vessels. In the United States
until 2018, the Graftmaster stent was the only covered stent available.
The Graftmaster is a balloon-expandable stent that consists of single
PTFE layering between two coaxial 316 L stainless steel. The most recently FDA-approved covered stent is the PK Papyrus stent, which consists of an ultrathin (60 μm) strut cobalt‑chromium design covered with
polyurethane matrix [11].
In our analysis, inability to deliver the stent was the primary mechanism of failure accounting for 49% of reports and was more reported
with Graftmaster. Poor deliverability is a known limitation of the
Graftmaster stent, especially in calciﬁed and tortuous vessels. The
Graftmaster stent has a large crossing proﬁle (1.63–1.73 mm) and
two-stent layers, limiting its ﬂexibility. The PK Papyrus has a lower
crossing proﬁle (1.18 to 1.55 mm) and single stent design covered on
the abluminal side with a polyurethane layer, rendering it compatible
with 5 Fr. guide up to 4 mm stents and 6 Fr. guide for the 4.5- and 5mm stents. Previous observational studies have also reported shorter
delivery times with PK Papyrus [12].
The second most common failure mechanism of covered stents was
stent dislodgment, which was more reported with PK Papyrus. In the
early experience of PK Papyrus, it was successfully delivered and sealed
the perforation in 95.0% and 91.3% of cases, respectively [13], with only
three cases of stent dislodgement (3.9%). Our study represents a real-life
experience in the United States since the device's approval, and further
investigation into the possible causes of the stent's easy dislodgement is
warranted.
Previous observational studies have shown that PK Papyrus was associated with a lower risk of pericardial effusion, cardiac arrest, and
emergency surgery than the Graftmaster [12,14]. There was no difference in the risk of emergency surgery or pericardiocentesis between
both stents in our analysis. In-hospital mortality, however, was found
to be lower in the PK Papyrus reports. This could be related to the
high incidence of failure to deliver the Graftmaster stent, which can be
disastrous in emergent situations. We could not assess the difference
in long-term outcomes in both stents given the database limitations. A
previous meta-analysis suggested a higher risk of stent thrombosis
and in-stent restenosis with Graftmaster compared with the PK Papyrus
stent [14].
The best treatment of CAP is avoidance, with proper balloon sizing
and utilizing intravascular imaging. However, should a perforation
occur, the operator should be well equipped to treat it effectively. Having covered stents available as well as understanding the limitations of
the available devices is crucial. It is essential to have strong support and

3.1. Mechanisms of failure and clinical outcomes
The most common failure mechanism was failure to deliver the stent
(138 reports, 46.2%). It was reported in 59.1% of the Graftmaster reports
and 6.8% of the Papyrus PK reports. Stent dislodgement (67 reports,
22.4%) was more reported with PK Papyrus compared with the
Graftmaster (75.7% vs. 4.9%) and was managed by device retrieval or
crushing the stent. There were 58 reports of failure to seal the perforation (19.9%) with no difference in the incidence for each stent (52

Table 1
Reports on coronary covered stents failure in the MAUDE registry.
Overall
(n = 299)

Graftmaster PK
(n = 225)
Papyrus
(n = 74)

P-value

138 (46.2)
67 (22.4)
59 (19.7)
9 (3.0)
7 (2.3)
1 (0.3)
6 (2.0)
3 (1.0)
4 (1.8)
7 (2.3)
2 (0.7)

133 (59.1)
11 (4.9)
52 (23.1)
7 (3.1)
5 (2.2)
1 (0.4)
6 (2.7)
3 (1.3)
5 (1.7)
7 (3.1)
2 (0.9)

5 (6.8)
56 (75.7)
7 (9.5)
2 (2.7)
2 (2.7)
0 (0)
0 (0)
0 (0)
1 (1.4)
0 (0)
0 (0)

<0.001
<0.001
0.110
1.000
0.684
–
–
–
1.000
0.199
–

3 (1.0)
2 (0.9)
128 (42.8) 112 (49.8)

1 (1.4)
16 (21.6)

40 (13.4)
62 (20.7)
14 (4.7)

29 (12.9)
54 (24.0)
13 (5.8)

11 (14.9)
8 (10.8)
1 (1.4)

0.575
<
0.001
0.695
0.014
0.201

5 (1.7)
4 (1.8)
108 (36.1) 95 (42.2)

1 (1.4)
13 (17.6)

1.000
<0.001

34 (11.4)

29 (12.9)

5 (6.8)

0.205

9 (3.0)
27 (9.0)

3 (1.3)
11 (4.9)

6 (8.1)
16 (21.6)

0.008
<0.001

Alternate management of perforation
Treated with coils, n (%)
3 (1.0)
Balloon tamponade only, n (%)
41 (13.7)

3 (1.3)
39 (17.3)

0 (0)
2 (2.7)

–
0.001

Clinical outcomes
IABP required, n (%)
ECMO required, n (%)
Pericardiocentesis, n (%)
Surgery, n (%)
Death, n (%)

4 (1.8)
3 (1.3)
2 (0.9)
23 (10.2)
53 (23.6)

0 (0)
0 (0)
0 (0)
5 (6.8)
4 (5.4)

0.575
–
–
0.492
<0.001

Mechanism of failure
Failure to deliver the stent, n (%)
Device dislodgment, n (%)
Failure to seal perforation, n (%)
Failure to expand the stent, n (%)
Material deformation, n (%)
Proximal shaft break, n (%)
Mid-shaft break, n (%)
Dissection or perforation, n (%)
No re-ﬂow, n (%)
Used past expiration date, n (%)
Damaged prior to use, n (%)
Vessel (n = 163)
Left main artery, n (%)
Left anterior descending artery,
n (%)
Left circumﬂex artery, n (%)
Right coronary artery, n (%)
Vein graft, n (%)
Management
Same stent deployed, n (%)
Same type of covered stent
deployed n (%)
Another type of covered stent
deployed n (%)
Stent crushed, n (%)
Stent retrieved, n (%)

4 (1.3)
3 (1.0)
2 (0.7)
28 (9.4)
57 (19.1)
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possibly guide extensions in situations when perforation is anticipated
(e.g., severely calciﬁed vessels). Although lacking the denominator of
all cases of perforations, the high incidence of in-hospital death in our
study (20%) is alarming. It highlights the need for improved management of coronary perforations. Our study suggests that the PK Papyrus
might be the preferred option in managing CAP, giving its better deliverability, albeit at the cost of a higher risk of dislodgment. Different measures should be taken to avoid dislodgement of the Papyrus PK stent,
including guide extensions and avoidance of negative preparation of
the stent.
4.1. Limitations
Our study is limited by the retrospective analysis from the MAUDE
database with its inherent selection bias resulting from optional
reporting by healthcare professionals. Second, the association between
the device failure and clinical adverse events could not be adjudicated.
Third, most of the variables are self-reported and could not be determined in each report. Fourth, the incidence of device failure cannot be
determined as the study lacks a denominator. Finally, the classiﬁcation
of perforations, according to the Ellis classiﬁcation, was not reported
consistently and could not be analyzed.

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.carrev.2021.04.002.
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4.2. Conclusions
The most common failure mechanisms of covered stents were the
failure of delivery, stent dislodgement, and failure to seal the perforation. Failure of delivery was more common with the Graftmaster,
while stent dislodgement was more common with the PK Papyrus stent.
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